Table 2. Results . All patients, n = 105... | American Society of Hematology

Table 2.

	All patients, n = 105		MUDs, n = 38	Related
	All patients, n = 105		MUDs, n = 38	CB, n = 15		Matched, n = 32	Mismatched, n = 20
Median time to neutrophil engraftment	15 (9-40)	21 (15-40)	15 (9-26)	14 (10-28)	13 (9-22)
Median time to PLT greater than 20K	22 (4-163)	32 (12-133)	26 (4-91)	15 (7-163)	23 (8-117)
Acute GVHD, n = 94
Grade 0	37 (39%)	3	10	16	8
Grade I	17 (18%)	2	8	3	4
Grade II	22 (24%)	6	9	3	4
Grade III-IV	18 (19%)	1	10	4	3
Disease response
Complete remission	23 (22%)	5	6	4	8
Continuous CR	60 (57%)	9	23	20	8
No response	5 (5%)	0	2	3
Early death†	13 (12%)	0	5	5	3
Graft failure	3 (3%)	1	1	0	1
Not evaluable	1 (1%)	0	1	0	0

	All patients, n = 105		MUDs, n = 38	Related
	All patients, n = 105		MUDs, n = 38	CB, n = 15		Matched, n = 32	Mismatched, n = 20
Median time to neutrophil engraftment	15 (9-40)	21 (15-40)	15 (9-26)	14 (10-28)	13 (9-22)
Median time to PLT greater than 20K	22 (4-163)	32 (12-133)	26 (4-91)	15 (7-163)	23 (8-117)
Acute GVHD, n = 94
Grade 0	37 (39%)	3	10	16	8
Grade I	17 (18%)	2	8	3	4
Grade II	22 (24%)	6	9	3	4
Grade III-IV	18 (19%)	1	10	4	3
Disease response
Complete remission	23 (22%)	5	6	4	8
Continuous CR	60 (57%)	9	23	20	8
No response	5 (5%)	0	2	3
Early death†	13 (12%)	0	5	5	3
Graft failure	3 (3%)	1	1	0	1
Not evaluable	1 (1%)	0	1	0	0

GVHD indicates graft-versus host-disease; CR, complete remission; PD, progressive disease; CB, cord blood; MUD, matched unrelated donor.

Not evaluable (engraftment failure, early death, or no response to transplant): N = 11.

Death prior to day 30.